Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II extension study of MK-2578 for maintenance treatment of anemia in hemodialysis patients with chronic kidney disease
2009-016376-76Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2010
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MK2578 in anemia of renal disease (2 arms), sponsored by Merck & Co. Primary endpoints: Hemoglobin maintenance within target range and Safety and tolerability of MK-2578. Started Mar 2010; status: terminated.
02
Drugs
MK2578
03
Conditions
anemia of renal disease
Beyond the preview
Go deeper on 2009-016376-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016376-76.